drug · small molecule
DEFLAZACORT
Marketedupdated 3mo agoby $AMRX Amneal Pharmaceuticals, Inc.🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for muscular dystrophy and duchenne muscular dystrophy and 3 investigational indications.
indications
investigational
Duchenne Muscular Dystrophy
targets
Glucocorticoid receptor
all catalysts(3)
Patent cliff
source: FDA Orange BookFDA exclusivities (5)
- Jun 7, 2026ODE-252Orphan Drug (7y)
- Jun 7, 2026ODE-252Orphan Drug (7y)
- Jun 7, 2026ODE-252Orphan Drug (7y)
- Jun 7, 2026ODE-252Orphan Drug (7y)
- Jun 7, 2026ODE-252Orphan Drug (7y)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 39m ago
Found something off?
comments(0)
5-min edit window · permanent after that